We are a novel drug R&D company focusing on discovering, developing and commercializing innovative therapeutics in oncology and autoimmune diseases. With a team of around 250 scientists and staff, our pipeline is comprised of novel oral compounds for cancer and inflammation in development in North America, Europe, Australia and China.

These products include a novel oral therapy for inflammatory bowel disease which is Phase III in the US & Europe; a novel oral selective c-Met inhibitor in phase II in Australia, China & the United States; four differentiated oral NCEs in oncology in Phase I & Phase II in China; and one oral NCE for inflammation in Phase I in Australia. Multiple NCEs are also in preclinical development.

After founding the company in 2002, we have built one of the largest and most experienced new drug R&D teams in China. We are led by a strong senior management team, all of whom have many years of experience succeeding at large US pharmaceutical and biotech companies. Our strategic partnerships have involved global, innovative companies such as AstraZeneca, Johnson & Johnson, Eli Lilly, Merck Serono and Nestlé Health Science in both oncology and inflammation.

和記黃埔醫藥（上海）有限公司（以下稱“和記黃埔醫藥”）是中國最為領先的新藥研發企業之一。公司致力于研發具有自主知識產權保護的治療癌癥和自身免疫性疾病的創新藥物。目前公司共有研發人員250余名。

和記黃埔醫藥的在研新藥包括：在美國和歐洲進入臨床三期試驗的用于治療潰瘍性結腸炎的新型口服藥物；在澳大利亞、中國和美國進行臨床二期試驗的新型抗癌藥物c-Met口服抑制劑；在中國進行臨床一期和二期試驗的四個小分子口服腫瘤抑制劑；在澳大利亞進行臨床一期試驗的炎癥領域新型口服小分子藥物以及多個處于臨床前研究階段的小分子藥物。

和記黃埔醫藥成立于2002年，經過多年發展，逐漸發展成為中國最大、最有經驗的新藥研發企業之一。公司擁有一流的創新藥物研發管理團隊，管理團隊成員皆有在美國大型制藥公司或生物公司的管理經驗。近幾年來，和記黃埔醫藥與全球知名醫藥研發機構如雀巢、阿斯利康、美國強生、美國禮來等建立了戰略合作伙伴關系，共同研發造福于全球病患的創新藥物。

www.hmplglobal.com
www.Chi-med.com